SCHEMBL19902586

SCHEMBL19902586

O=C(N[C@H]1CC[C@H](c2n[nH]c(=O)c3ccccc32)CC1)c1cccc(-n2cccn2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.45
KAT6A Q92794 2/20 0.43
DRD2 P14416 2/20 0.41
HTR2A P28223 2/20 0.41
DRD3 P35462 2/20 0.41
PARP1 P09874 2/20 0.40
DGAT2 Q96PD7 1/20 0.40
NPC1 O15118 2/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MLLT3 P42568 1/20 0.38
MLLT1 Q03111 1/20 0.38
TNKS O95271 1/20 0.38
MAP3K5 Q99683 1/20 0.37
CHRM1 P11229 1/20 0.37
RIPK2 O43353 1/20 0.37
CHEK1 O14757 1/20 0.37
ALDH1A1 P00352 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAPK8 P45983 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17452846 0.89 ROCK2 (0.59) ROCK2KAT6ADRD2HTR2ADRD3
SCHEMBL19902582 0.85 ROCK1 (0.47) ROCK2NPC1RAB9ASMN1; SMN2MAP3K5
SCHEMBL19902627 0.83 PARP1 (0.54) ROCK2DRD2HTR2ADRD3PARP1
SCHEMBL19902632 0.77 KMT2A (0.51) ROCK2PARP1NPC1RAB9ASMN1; SMN2
SCHEMBL19902573 0.77 MAPK8 (0.43) ROCK2PARP1NPC1RAB9ASMN1; SMN2
SCHEMBL19902714 0.76 ROCK1 (0.58) ROCK2HTR2ARAB9AL3MBTL1ROCK1
SCHEMBL19902589 0.76 ROCK1 (0.58) ROCK2DRD2HTR2ADRD3NPC1
SCHEMBL19902622 0.76 MAPK14 (0.54) ROCK2CHEK1ALDH1A1
SCHEMBL19902707 0.76 KDM5A (0.49) ROCK2CHEK1ALDH1A1
SCHEMBL20229915 0.76 ROCK2 (0.51) ROCK2MAP3K5MAPK8ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 ROCK2 3/4885KAT6A 2556/4885DRD2 3471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.